<DOC>
	<DOCNO>NCT00002093</DOCNO>
	<brief_summary>To compare toxicity profile ( severity time onset initiation therapy ) daunorubicin ( liposomal ) combination chemotherapy doxorubicin/bleomycin/vincristine ( ABV ) , regimens administer combination antiretroviral therapy . To compare duration response , response rate , time response .</brief_summary>
	<brief_title>A Randomized Phase III Clinical Trial Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine ( ABV ) Treatment HIV-Associated Kaposi 's Sarcoma .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection . Advanced Kaposi 's sarcoma . Prior Medication : Allowed : Prior intralesional vinblastine . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute intercurrent infection genital herpes . Uncompensated cardiovascular , hepatic , renal , pulmonary disease unrelated Kaposi 's sarcoma . Symptomatic peripheral neuropathy . Any condition compromise ability give inform consent complete study . Concurrent Medication : Excluded : Concurrent ganciclovir . Patients follow prior condition exclude : Symptomatic AIDSdefining opportunistic infection within 2 week entry . History malignancy Kaposi 's sarcoma , basal cell carcinoma , carcinoma situ cervix . Prior Medication : Excluded : Prior systemic chemotherapy . Intralesional therapy within 7 day prior study entry . Growth factor ( GCSF GMCSF ) , immune modifier , investigational agent within 14 day prior study entry . Interferon preparation ( alpha beta ) within 28 day prior study entry . Prior Treatment : Excluded within 7 day prior study entry : Radiation . Local therapy ( e.g. , cryotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Daunorubicin</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>